SUMMARY
ANTITUSSIVE HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE TABLETS
Hydrocodone bitartrate and homatropine methylbromide tablets contains hydrocodone (dihydrocodeinone) bitartrate, a semisynthetic centrally-acting narcotic antitussive. Homatropine methylbromide is included in a subtherapeutic amount to discourage deliberate overdosage.
Each hydrocodone bitartrate and homatropine methylbromide tablet for oral administration contains:
Hydrocodone bitartrate, USP 5 mg
Homatropine methylbromide, USP 1.5 mg
Hydrocodone bitartrate and homatropine methylbromide tablets are indicated for the symptomatic relief of cough.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Antitussive Hydrocodone and Homatropine Methylbromide (Hydrocodone / Homatropine)
Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers. [2003.01] RATIONALE: The subjective, psychomotor, and physiological effects of prescription compounds containing the opioid hydrocodone have not been studied in a population of non-drug-abusing people who might be prescribed these compounds for cough or pain relief. OBJECTIVES: To characterize the effects of a hydrocodone combination product, Hycodan, which contains hydrocodone and a peripherally-acting anticholinergic, homatropine, in non-drug-abusing volunteers... CONCLUSIONS: Hycodan at the highest dose tested had effects similar to that of a prototypic mu agonist, morphine. Both drugs produced pleasant (including drug liking) as well as unpleasant subjective effects. Post-session ratings of overall liking and "want to take drug again" were not significant.
Clinical Trials Related to Antitussive Hydrocodone and Homatropine Methylbromide (Hydrocodone / Homatropine)
Effects of Su-Huang Antitussive Capsule on Cough Variant Asthma [Recruiting]
This study aims to observe the therapeutic effect of Su-Huang antitussive capsule on cough
variant asthma.
The investigators hypothesize:
Cough score and cough reflex sensitivity will be improved after treatment with Su-Huang
antitussive capsule.
Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment [Not yet recruiting]
Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection [Recruiting]
The purpose of this research study is to explore the mechanism of action of Mucinex, an
oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract
infections.
The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study [Recruiting]
This is a 14-day, randomized, placebo-controlled, parallel group, masked clinical trial of
oral guaifenesin for the therapy of Chronic Rhinitis in 36 children between the ages of 7
and 18 years. The study investigates the effectiveness of guaifenesin in the relief of nasal
symptoms in children with CRS using the sinonasal 5 survey (SN-5) in comparison to nasal
airway volume, and biophysical properties of nasal secretion. The investigators hypothesize
that Guaifenesin use over a period of 14 days improves subjective nasal complaints in
pediatric patients with chronic rhinitis and nasal congestion, as measured by the SN-5
survey compared to use of placebo. There will be an observed improvement in nasal volume and
cross-sectional area following use of guaifenesin, and nasal secretions will have more
favorable mucociliary and sneeze clearability compared to use of placebo.
Comparison Between Dexchlorpheniramine and Dexchlorpheniramine/Pseudoephedrine/Guaifenesin in Respiratory Infections [Not yet recruiting]
Patients with allergic rhinitis frequently present exacerbation of the atopic symptoms
during viral infections of the upper respiratory tract. Also, allergic rhinitis makes the
mucosa more reactive to infectious agents and potentiates mucus production.
The combination of dexchlorpheniramine, pseudoephedrine and guaifenesin elicits
antihistaminic, decongestant and expectorant effects. The study hypothesizes is that this
product is superior to dexchlorpheniramine alone in the relief of allergic symptoms and in
promoting mucus elimination in atopic patients with viral infections of the upper
respiratory tract.
|
|
|
|
Page last updated: 2006-01-31
|